JohnDHainsworthMD

Clinical Trials

• Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer Start of enrollment: 2001 Sep 01

  Terminated

  Phase 2

• Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer Start of enrollment: 2001 Apr 01

  Completed

  Phase 2

• Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer Start of enrollment: 1999 Oct 01

  Completed

  Phase 2

• OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2003 Feb 01

  Completed

  Phase 2

• Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma Start of enrollment: 2000 Aug 01

  Completed

  Phase 2

• Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer Start of enrollment: 2004 May 01

  Completed

  Phase 2

• Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma Start of enrollment: 2004 Jun 01

  Completed

  Phase 1, Phase 2

• Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer Start of enrollment: 2003 Oct 01

  Completed

  Phase 2

• Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients Start of enrollment: 2001 Aug 01

  Completed

  Phase 2

• Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer Start of enrollment: 2003 Mar 01

  Completed

  Phase 2

• Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer Start of enrollment: 2003 Aug 01

  Completed

  Phase 2

• Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma Start of enrollment: 2002 Apr 01

  Completed

  Phase 2

• Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2002 Jan 01

  Completed

  Phase 2

• Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2003 Apr 01

  Completed

  Phase 2

• A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma Start of enrollment: 2005 Sep 01

  Completed

  Phase 2

• Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma Start of enrollment: 2003 Oct 01

  Completed

  Phase 2

• Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Start of enrollment: 2004 Apr 01

  Completed

  Phase 2

• Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma Start of enrollment: 1998 Dec 01

  Completed

  Phase 2

• Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma Start of enrollment: 2002 Mar 01

  Completed

  Phase 2

• Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma Start of enrollment: 2004 May 01

  Completed

  Phase 2

• Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site Start of enrollment: 2003 Sep 01

  Completed

  Phase 3

• Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site Start of enrollment: 2004 Sep 01

  Completed

  Phase 2

• Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site Start of enrollment: 2004 Apr 01

  Completed

  Phase 2

• Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma Start of enrollment: 2006 May 01

  Completed

  Phase 2

• Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site Start of enrollment: 2006 Jul 01

  Completed

  Phase 2

• Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer Start of enrollment: 2006 Oct 01

  Completed

  Phase 2

• Treatment of Head & Neck Cancer With Chemotherapy and Radiation Start of enrollment: 2006 Dec 01

  Completed

  Phase 2

• Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer Start of enrollment: 2006 Dec 01

  Completed

  Phase 1, Phase 2

• Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer Start of enrollment: 2007 Feb 01

  Completed

  Phase 2

• High-dose Bevacizumab in Advanced Renal Carcinoma Patients Start of enrollment: 2007 Feb 01

  Completed

  Phase 2

• Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme Start of enrollment: 2007 Apr 01

  Completed

  Phase 2

• Vinflunine in Hormone Refractory Prostate Cancer (HRPC) Start of enrollment: 2007 May 01

  Completed

  Phase 2

• LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Start of enrollment: 2008 Jan 01

  Completed

  Phase 2

• RAD001 Plus Bevacizumab in Metastatic Melanoma Start of enrollment: 2008 Jan 01

  Completed

  Phase 2

• Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2008 Sep 01

  Completed

  Phase 2

• Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site Start of enrollment: 2008 Aug 01

  Completed

  Phase 2

• RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM Start of enrollment: 2009 Jan 01

  Completed

  Phase 2

• Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary Start of enrollment: 2009 Feb 01

  Completed

  Phase 2

• Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma Start of enrollment: 2010 Jan 01

  Terminated

  Phase 2

• Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma Start of enrollment: 2010 Feb 01

  Completed

  Phase 2

• Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer Start of enrollment: 2011 Jan 01

  Completed

  Not Applicable

• Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme Start of enrollment: 2011 Dec 01

  Completed

  Phase 1, Phase 2

• A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma Start of enrollment: 2013 Feb 01

  Terminated

  Phase 2

• Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel Start of enrollment: 2014 Apr 01

  Withdrawn

  Phase 2

• Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2014 Oct 01

  Completed

  Phase 1

• A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13

  Completed

  Phase 3

• A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14

  Active, not recruiting

  Phase 3

• Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma Start of enrollment: 2017 Jan 12

  Terminated

  Phase 2

• Join now to see all